Publikationen in Zusammenarbeit mit Forschern von Netherlands Cancer Institute (7)

2022

  1. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

    The Lancet. Oncology, Vol. 23, Núm. 1, pp. 149-160

2021

  1. Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024](S0923753421015532)(10.1016/j.annonc.2021.05.353)

    Annals of Oncology

  2. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

    Annals of Oncology, Vol. 32, Núm. 8, pp. 1015-1024

  3. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Overall survival with ribociclib plus fulvestrant in advanced breast cancer

    New England Journal of Medicine, Vol. 382, Núm. 6, pp. 514-524

2018

  1. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3

    Journal of Clinical Oncology, Vol. 36, Núm. 24, pp. 2465-2472

2005

  1. Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005

    Annals of Oncology, Vol. 16, Núm. 10, pp. 1569-1583